This is an important observational study which points towards higher mobidity and mortality in patients with acute coronary syndromes who undergo transfusion. The results obtained, though not definitive due to the nature of the study, strongly suggest the need for a randomized controlled clinical trial of restrictive versus liberal transfusion in this patient population. – […]
The debate of blood transfusion and cancer recurrence continues in this study. The authors found LN status and >3 units of blood transfused to be poor prognostic factors, but this was a retrospective, uncontrolled study. – David H. Henry
Effect of recombinant human erythropoietin on quality of life in cancer patients receiving chemotherapy: Results of a randomized, controlled trial.
A nice demonstration again in a placebo controlled trial that recombinant EPO is safe and effective in anemic cancer patients on chemorx. The three times weekly dose is more commonly replaced now with the once weekly dose, starting at 40,000 U SQ. – David H. Henry